Patents by Inventor Hirokazu Matsumoto

Hirokazu Matsumoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090239839
    Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.
    Type: Application
    Filed: February 24, 2009
    Publication date: September 24, 2009
    Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Fumio ITOH, Shuji Hinuma, Naoyuki Kanzaki, Hiroshi Mabuchi, Hiromi Yoshida, Hirokazu Matsumoto, Takeshi Wakabayashi
  • Publication number: 20090227501
    Abstract: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which are less toxic and safe, and can be used as, e.g., agents for preventing/treating upper digestive tract disorders, antibacterial agents to Helicobacter pylori, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide or receptor of the present invention and the DNA of the present invention can be used as, e.g., gastric acid secretion promoters and can be used as, e.g., agents for preventing/treating dyspepsia, bone metabolism disorders, anemia, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide of the present invention, etc.
    Type: Application
    Filed: June 24, 2008
    Publication date: September 10, 2009
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Hirokazu Matsumoto, Koh Takagi, Masaaki Mori
  • Publication number: 20090197395
    Abstract: A method of manufacturing a device includes: a laser beam-machined groove forming step of irradiating a wafer with a laser beam from the back side of the wafer along planned dividing lines so as to form laser beam-machined grooves along the planned dividing lines; an etching step of etching a back-side surface of the wafer having been subjected to the laser beam-machined groove forming step, so as to remove denatured layers formed at processed surfaces of the laser beam-machined grooves; an adhesive film attaching step of attaching an adhesive film to the back-side surface of the wafer having been subjected to the etching step, and adhering the adhesive film side of the wafer to a surface of a dicing tape; and an adhesive film rupturing step of expanding the dicing tape so as to rupture the adhesive film along individual devices.
    Type: Application
    Filed: January 15, 2009
    Publication date: August 6, 2009
    Applicant: DISCO CORPORATION
    Inventors: Masaru Nakamura, Hirokazu Matsumoto
  • Publication number: 20090191692
    Abstract: A method of processing a wafer having a plurality of devices which are composed of a laminate consisting of an insulating film and a functional film on the front surface of a substrate, along streets for sectioning the plurality of devices, the method comprising a first blocking groove forming step for forming a first blocking groove for dividing the laminate in a one-side portion in the width direction of a street of the wafer held on a chuck table by moving the chuck table in a first direction in the processing-feed direction while activating a first laser beam application means; and a second blocking groove and dividing groove forming step for forming a second blocking groove which divides the laminate in the other-side portion in the width direction of the street of the wafer which has undergone the first blocking groove forming step by moving the chuck table in a second direction in the processing-feed direction while activating the first laser beam application means and at the same time, forming a divid
    Type: Application
    Filed: December 19, 2008
    Publication date: July 30, 2009
    Inventors: Kentaro IIzuka, Hirokazu Matsumoto, Ryugo Oba
  • Publication number: 20090138757
    Abstract: There is provided a method executed in a cluster system comprising a first computer and at least one second computer that stores the data transmitted from the first computer. The method comprising the steps of: judging whether the failure-occurred processing is restarted by the first computer or the failure-occurred processing is switched over by the second computer based on the system information; receiving the stored data from the second computer and re-executing the processing in which the failure has occurred by the first computer, in the case of which it is judged that the processing in which the failure has occurred is restarted by the first computer; and executing, by the second computer, the processing in which the failure has occurred, in the case of which it is judged that the processing in which the failure has occurred is switched over by the at least one second computer.
    Type: Application
    Filed: March 3, 2008
    Publication date: May 28, 2009
    Inventors: Hirokazu Matsumoto, Tsunehiko Baba, Shinji Hamada, Takashi Ichimura, Noriaki Takahashi
  • Patent number: 7342105
    Abstract: The antibody of the present invention, which specifically reacts with the N-terminal or C-terminal partial peptide of TGR23-2 ligand, is useful in detecting and quantifying the TGR23-2 ligand. Moreover, it is useful as a preventing/treating agent and a diagnostic agent for cancer, etc.
    Type: Grant
    Filed: February 26, 2004
    Date of Patent: March 11, 2008
    Assignee: Takeda Chemcial Industries, Ltd.
    Inventors: Hirokazu Matsumoto, Eri Hashimoto, Masaaki Mori, Chieko Kitada
  • Patent number: 7323541
    Abstract: The present invention aims at providing a novel polypeptide, a receptor, a DNA thereof, and the like. Specifically, the present invention provides a polypeptide having a binding ability to the protein represented by SEQ ID NO: 1 or SEQ ID NO: 3, or its amide, its ester or its salt, a polynucleotide encoding the polypeptide, an antisense polynucleotide or an antibody to the polypeptide, a screening of agent for prevention and/or treatment of cancer, obesity, etc., which comprises using the above, and the like. The polypeptide, receptor, polynucleotide, antisense polynucleotide, antibody and the like are useful for an agent of prevention and/or treatment of cancer, obesity and the like. Further, they are useful for a screening of an agent for prevention and/or treatment of cancer, obesity and the like.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: January 29, 2008
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Masaaki Mori, Kozo Hayashi, Hiroyuki Miya, Shuji Sato, Chieko Kitada, Hirokazu Matsumoto, Toshimi Nagi, Yukio Shimomura
  • Publication number: 20070129348
    Abstract: An agent for modulating the function of an RFRP receptor, characterized by containing either a compound represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted benzene ring; X represents oxygen, S(O)n (n is an integer of 0 to 2), or NR3 (R3 represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group); and R1 and R2 each represents hydrogen, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group] or a salt of the compound.
    Type: Application
    Filed: April 15, 2004
    Publication date: June 7, 2007
    Inventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Hiroshi Mabuchi, Hiromi Yoshida, Hirokazu Matsumoto, Takeshi Wakabayashi
  • Publication number: 20070117840
    Abstract: A compound represented by the formula (I): wherein ring A represents an aromatic ring; X represents a bond, oxygen, NR4 (R4 represents hydrogen, a hydrocarbon group, or a heterocyclic group), or alkylene; R1 represents a hydrocarbon group, or a heterocyclic group; R2 represents —COYR5 (Y represents a bond, alkylene, oxygen, sulfur, or NR6 (R6 represents hydrogen, a hydrocarbon group, or a heterocyclic group), and R5 represents a hydrocarbon group, or a heterocyclic group), a hydrocarbon group, or a heterocyclic group; and R3 represents a hydrocarbon group, a heterocyclic group, optionally substituted hydroxy, optionally substituted amino, or —S(O)nR7 (R7 represents a hydrocarbon group, or a heterocyclic group, and n is 0 to 2), a salt of the compound, or a prodrug or either is useful as an agent for modulating the function of an RFRP receptor.
    Type: Application
    Filed: March 16, 2004
    Publication date: May 24, 2007
    Inventors: Fumio Itoh, Shuji Hinuma, Naoyuki Kanzaki, Yoshihiro Banno, Hiromi Yoshida, Hirokazu Matsumoto
  • Publication number: 20070072865
    Abstract: The present invention provides a compound represented by the formula: wherein R1 is an acyl group, R2 is a hydrocarbon group which may be substituted or the like, R3 is a hydrocarbon group which may be substituted or the like, R4 is a hydrocarbon group which may be substituted or the like, n is from 0 to 4, and X is an oxygen atom, a sulfur atom or the like, or a salt thereof. The invention also provides a compound which has a TGR23 antagonist activity and thus is useful for prevention and treatment of cancer.
    Type: Application
    Filed: August 26, 2004
    Publication date: March 29, 2007
    Inventors: Kohji Fukatsu, Yutaka Nakayama, Naoki Tarui, Masaaki Mori, Hirokazu Matsumoto, Osamu Kurasawa, Hiroshi Banno
  • Publication number: 20070042947
    Abstract: A compound or its salts that inhibit the activity of the polypeptide or receptor of the present invention and the antibody of the present invention as well as the antisense DNA of the present invention are useful as, e.g., gastric acid secretion inhibitors, mucosa protectants, mineral absorption promoters, etc., which are less toxic and safe, and can be used as, e.g., agents for preventing/treating upper digestive tract disorders, antibacterial agents to Helicobacter pylori, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide or receptor of the present invention and the DNA of the present invention can be used as, e.g., gastric acid secretion promoters and can be used as, e.g., agents for preventing/treating dyspepsia, bone metabolism disorders, anemia, etc. A compound or its salts that promote the activity of the polypeptide or receptor of the present invention, the polypeptide of the present invention, etc.
    Type: Application
    Filed: March 11, 2004
    Publication date: February 22, 2007
    Applicant: Takeda Pharmaceutical Company Limited
    Inventors: Hirokazu Matsumoto, Koh Takagi, Masaaki Mori
  • Patent number: 7173112
    Abstract: The present invention intends to provide a novel monoclonal antibody having a binding specificity to GALP or its derivative, which is useful in developing therapeutic agents, preventive agents or diagnostic agent for diseases associated with GALP or its derivative, and a method of quantifying GALP using the antibody. More specifically, the present invention provides an antibody specifically reacting with a partial peptide in the C-terminal region of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, or its derivative, and a method of quantifying GALP or its derivative.
    Type: Grant
    Filed: September 25, 2002
    Date of Patent: February 6, 2007
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hirokazu Matsumoto, Yasuko Horikoshi, Chieko Kitada, Tetsuya Ohtaki
  • Publication number: 20070014799
    Abstract: The present invention provides a novel antibody useful in developing therapeutic, preventive and diagnostic agents for diseases associated with human ZAQL-2, a method of quantifying ZAQL-2 by using the antibody, etc. More particularly, the present invention provides an antibody reacting specifically with human ZAQL-2 or its derivatives, a method of quantifying ZAQL-2 by using the antibody, a pharmaceutical drug comprising the antibody, and so on.
    Type: Application
    Filed: October 21, 2004
    Publication date: January 18, 2007
    Inventors: Hirokazu Matsumoto, Jiro Noguchi, Yasushi Masuda
  • Publication number: 20060287227
    Abstract: Metastin, compounds that promote the activity of metastin or its receptors and the like are excellent gonadal function improving agents, ovulation inducers or promoters, gonadotropic hormone secretion promoters, gonadotropic hormone secretion inhibitors, sex hormone secretion promoters, sex hormone secretion inhibitors, etc., and can be used as agents for preventing/treating sterility, hormone-sensitive cancers, endometriosis, etc. Metastin and its receptors are useful for screening for these pharmaceuticals.
    Type: Application
    Filed: March 11, 2004
    Publication date: December 21, 2006
    Inventors: Tetsuya Ohtaki, Hisanori Matsui, Hirokazu Matsumoto, Chieko Kitada
  • Publication number: 20060275286
    Abstract: The present invention aims at providing an antibody, by which metastin or its derivative can be quantified specifically with a high sensitivity, a method of detecting/quantifying metastin or its derivative using the antibody, and a diagnostic agent (e.g., a diagnostic for pregnancy) the same. Specifically, an antibody capable of specifically reacting with a partial peptide at the N-terminus or C-terminus of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or its derivative, and a method of detecting/quantifying metastin or its derivative using the antibody as well as a diagnostic agent using the same.
    Type: Application
    Filed: August 2, 2006
    Publication date: December 7, 2006
    Applicant: Takeda Chemical Industries, Ltd.
    Inventors: Hirokazu Matsumoto, Yasuko Horikoshi, Chieko Kitada, Tetsuya Ohtaki
  • Patent number: 7130752
    Abstract: In a measuring-instrument remote-calibration system and measuring-instrument remote-calibration method, a measuring standard quantity is converted into a parameter adapted for communication, or based on measuring standard quantity, a parameter adapted for communication is generated and sent to a remote place. Alternatively, when the measuring standard quantity is not suitable for communication, it is converted into a form adapted for transportation and the converted measuring standard quantity is sent to a remote place. After the converted measuring standard quantity reaches the place, it is restored to the original measuring standard quantity, thus enabling calibration. The result of the calibration is certified.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: October 31, 2006
    Assignee: National Institute of Advanced Industrial Science and Technology
    Inventors: Haruo Yoshida, Hirokazu Matsumoto, Yoshio Hino, Masaru Arai, Masataka Nakazawa
  • Publication number: 20060241051
    Abstract: The present invention provides a metastin derivative in which the amino acids comprising metastin were modified by alternative chemical substituents resulting in metastin derivitives, having excellent blood stability and exhibiting cancer metastasis inhibiting action or cancer growth inhibiting action.
    Type: Application
    Filed: December 26, 2003
    Publication date: October 26, 2006
    Inventors: Chieko Kitada, Taiji Asami, Naoki Nishizawa, Tetsuya Ohtaki, Naoki Tarui, Hirokazu Matsumoto, Jiro Noguchi, Hisanori Matsui
  • Publication number: 20060217536
    Abstract: The antibody of the present invention has an extremely high binding ability to human ZAQL-1, can neutralize the activity of human ZAQL-1, and inhibits the action of human ZAQL-1. Therefore, the antibody is useful as a preventive or therapeutic agent or a diagnostic agent for, e.g., digestive diseases, diseases associated with angiogenesis, diseases relating to pregnancy, eating disorders, sleeping disorders, seasonal depression, reproductive dysfunction, endocrine diseases, senile dementia, Alzheimer's disease, various disorders caused by aging, cerebral circulatory disorders, head trauma, spinal injury, epilepsy, anxiety, depression, manic depression, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstral syndrome, glaucoma, cancer, AIDS, diabetes, etc.
    Type: Application
    Filed: January 21, 2004
    Publication date: September 28, 2006
    Inventors: Hirokazu Matsumoto, Yasuko Horikoshi
  • Patent number: 7112662
    Abstract: The present invention aims at providing an antibody, by which metastin or its derivative can be quantified specifically with a high sensitivity, a method of detecting/quantifying metastin or its derivative using the antibody, and a diagnostic agent (e.g., a diagnostic for pregnancy) the same. Specifically, an antibody capable of specifically reacting with a partial peptide at the N-terminus or C-terminus of a polypeptide having the amino acid sequence represented by SEQ ID NO: 1 or its derivative, and a method of detecting/quantifying metastin or its derivative using the antibody as well as a diagnostic agent using the same.
    Type: Grant
    Filed: September 18, 2002
    Date of Patent: September 26, 2006
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Hirokazu Matsumoto, Yasuko Horikoshi, Chieko Kitada, Tetsuya Ohtaki
  • Publication number: 20060177449
    Abstract: The antibody of the present invention, which is specifically reacting with the N-terminal or C-terminal partial peptide of TGR23-2 ligand, is useful in detecting and quantifying the TGR23-2 ligand. Moreover, it is useful as a preventing/treating agent and a diagnostic agent for cancer, etc.
    Type: Application
    Filed: February 26, 2004
    Publication date: August 10, 2006
    Inventors: Hirokazu Matsumoto, Eri Hashimoto, Masaaki Mori, Chieko Kitada